IPHARMA was authorized to conduct the Phase I clinical trial of medicinal product ИД 4025
In August 2016, IPHARMA LLC was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase I clinical trial of medicinal product ИД-4025.
Protocol № HCV-ИД4025-04 "Double-blind randomized placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of rising doses of ИД-4025 for single oral use in healthy subjects".
Study Objective: to evaluate the safety and tolerability of ИД-4025 for single use in healthy subjects.
The area of the study drug ИД 4025 use – infectious diseases.
IPHARMA LLC has a solid experience in conducting Phase I-III studies in this therapeutic area. The company specialists will conduct monitoring, data collection and study report preparation in accordance with international standards. Medical advisors will manage the medical expertise and the safety of the clinical study.